Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients

M. Romeo, F. Martinelli-Boneschi, M. Rodegher, F. Esposito, V. Martinelli, G. Comi, B. Colombo, L. Moiola, P. Rossi, A. Poggi, M. Radaelli, E. Perego, L. Straffi, G. Liberatore, D. Dalla Libera, D. De Feo

Research output: Contribution to journalArticlepeer-review

Abstract

Background and purpose: It is still unclear which patients benefit more from available disease-modifying treatments (DMTs) in multiple sclerosis (MS). Our objective is to identify the baseline clinical and magnetic resonance imaging (MRI) predictors of response to first-line DMTs in a cohort of relapsing-remitting (RR) MS patients in a real-world clinical setting. Methods: Consecutive naïve RRMS patients treated with interferon-beta or glatiramer acetate have been included and followed for 2years. Patients were grouped into responders (R) in case of absence of clinical and MRI activity, and non-responders (NR) if the on-treatment annualized relapse rate (ARR) reduction was

Original languageEnglish
Pages (from-to)1060-1067
Number of pages8
JournalEuropean Journal of Neurology
Volume20
Issue number7
DOIs
Publication statusPublished - Jul 2013

Keywords

  • Glatiramer acetate
  • Interferon-beta
  • MRI
  • Multiple sclerosis
  • Relapse
  • Treatment response

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint

Dive into the research topics of 'Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients'. Together they form a unique fingerprint.

Cite this